Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Onco-Innovations Ltd. ( (TSE:ONCO) ) just unveiled an announcement.
Onco-Innovations Limited has entered into a Start-Up Agreement with Avance Clinical Pty Ltd to advance its lead candidate, a Polynucleotide Kinase Phosphatase inhibitor, towards human trials. This collaboration aims to prepare the necessary regulatory and clinical documentation for trial readiness, targeting advanced-stage cancers with PTEN or SHP-1 deficiency. The agreement includes developing essential documents for regulatory evaluation and planning a pre-IND meeting with the FDA, marking a critical step in aligning the trial design with regulatory expectations.
More about Onco-Innovations Ltd.
Onco-Innovations Limited is a Canadian-based company focused on cancer research and treatment, specializing in oncology. The company is committed to the prevention and treatment of cancer through pioneering research and innovative solutions, with an exclusive worldwide license to patented technology targeting solid tumors.
Average Trading Volume: 90,606
Technical Sentiment Signal: Strong Sell
Find detailed analytics on ONCO stock on TipRanks’ Stock Analysis page.